Jazz Pharmaceuticals, Inc.’s working capital deficit rose 39.8%,
or US$8.9 million, from US$22.3 million at December 31, 2009, to
US$31.2 million at March 31, 2010.
provides timely updates on public companies reporting a working capital deficit to the U.S. Securities and Exchange Commission. Companies with minimum total assets of USD $5 million are covered. Liquidity Alert highlights significant events affecting liquidity, cash flows, estimated capital expenditures, and capital raising efforts.